ATC code None PubChem CID 2921148 ChemSpider 2194720 Molar mass 244.267 g/mol | CAS Number 433695-36-4 IUPHAR/BPS 5154 ChEMBL CHEMBL484928 | |
 | ||
BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 subtype. It has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.
References
BRL-50481 Wikipedia(Text) CC BY-SA